Table 3

Cox proportional hazards model: univariable analysis to evaluate factors associated with arthritis persistence

HR95% CIP value*
Female sex0.860.40 to 1.850.70
Age (years)1.020.99 to 1.050.12
BMI (kg/m2)0.950.88 to 1.020.17
Family history of autoimmunity0.550.13 to 2.310.41
TJC33 0.770.65 to 0.92 0.004
SJC33 1.00.92 to 1.091.0
Enthesitis0.650.24 to 1.760.40
Physician global assessment0.970.95 to 1.000.06
Patient global assessment0.990.97 to 1.010.30
CDAI0.950.90 to 1.000.07
ESR1.010.99 to 1.020.29
CRP (mg/dL)1.020.92 to 1.130.73
Duration ICI therapy (months)0.930.87 to 0.99 0.02
Combo versus Mono therapy0.290.12 to 0.72 0.008
ANA positivity1.770.52 to 5.980.36
CCP positivity1.760.23 to 13.370.58
irAEs (0, 1, 2 or more)0.610.39 to 0.95 0.03
Melanoma0.490.22 to 1.120.09
NSCLC0.890.36 to 2.200.80
Tumour response
(CR/PR vs SD/PD)
0.500.22 to 1.110.09
  • p-values in bold are statistically significant (<0.05).

  • *The outcome of interest was resolution of IA. Therefore, HRs <1 denote factors that associate with persistence of IA.

  • ANA, antinuclear antibody; BMI, body mass index; CCP, cyclic citrullinated peptide antibody; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; CR/PR, complete response and partial response; ESR, erythrocyte sedimentation rate; IA, inflammatory arthritis; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events; NSCLC, non-small cell lung cancer; SD/PD, stable disease and progressive disease; SJC, swollen joint count; TJC, tender joint count.